TNFRSF9 and plasma cell myeloma: These findings are in line with data from preclinical lymphoma and MM models in which CD137 stimulation enhanced the anti-lymphoma and -myeloma activity of anti-CD20 and anti-CD38 antibodies [9, 50, 51].